Invalid Symbol

Stock Research for MDVN

Current Price


Latest Update:


Featured Broker: TradeStation

Get the due diligence for another stock.


MDVN Stock Chart & Research Data

The MDVN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MDVN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


MDVN Due diligence Resources & Stock Charts

The MDVN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MDVN Detailed Price Forecast - CNN Money CNN View MDVN Detailed Summary - Google Finance
Yahoo View MDVN Detailed Summary - Yahoo! Finance Zacks View MDVN Stock Research & Analysis -

Stock Analysis

TradeIdeas View MDVN Trends & Analysis - Trade-Ideas Barrons View MDVN Major Holders - Barrons
NASDAQ View MDVN Call Transcripts - NASDAQ Seeking View MDVN Breaking News & Analysis - Seeking Alpha
Spotlight View MDVN Annual Report - OTC Report View MDVN OTC Short Report -
TradeKing View MDVN Fundamentals - TradeKing Charts View MDVN SEC Filings - Bar Chart
WSJ View Historical Prices for MDVN - The WSJ Morningstar View Performance/Total Return for MDVN - Morningstar
MarketWatch View the Analyst Estimates for MDVN - MarketWatch CNBC View the Earnings History for MDVN - CNBC
StockMarketWatch View the MDVN Earnings - StockMarketWatch MacroAxis View MDVN Buy or Sell Recommendations - MacroAxis
Bullish View the MDVN Bullish Patterns - American Bulls Short Pains View MDVN Short Pain Metrics -

Social Media Mentions

StockTwits View MDVN Stock Mentions - StockTwits PennyStocks View MDVN Stock Mentions - PennyStockTweets
Twitter View MDVN Stock Mentions - Twitter Invest Hub View MDVN Investment Forum News - Investor Hub
Yahoo View MDVN Stock Mentions - Yahoo! Message Board Seeking Alpha View MDVN Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for MDVN - Insider Cow View Insider Transactions for MDVN - Insider Cow
CNBC View MDVN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MDVN - OTC Markets
Yahoo View Insider Transactions for MDVN - Yahoo! Finance NASDAQ View Institutional Holdings for MDVN - NASDAQ

Stock Charts

FinViz View MDVN Stock Insight & Charts - StockCharts View MDVN Investment Charts -
BarChart View MDVN Stock Overview & Charts - BarChart Trading View View MDVN User Generated Charts - Trading View

Latest Financial News for MDVN

Medivation Founder Takes Helm at Axovant, Shares Spike
Posted on Monday April 10, 2017

David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.

How I'd Play Biotech Buyout Rumors
Posted on Sunday March 26, 2017

Answering questions from the Biotech Mailbag on FLXN and SGYP.

Posted on Wednesday December 31, 1969

Posted on Wednesday December 31, 1969

Pfizer to pay $14 billion for Medivation, whose drug Xtandi was discovered by UCLA
Los Angeles Times - Aug 22, 2016
Through the deal, Pfizer gains a drug that has generated about $2.2 billion in net sales worldwide over the last year. (Mark Lennihan / Associated Press).
Pfizer Beats Out Sanofi to Take Medivation for $14 Billion - Bloomberg

Medivation Inc. Licenses Clinical Stage Anti-PD-1 Immune Modulatory Monoclonal ...
Marketwired (press release) - Oct 23, 2014
SAN FRANCISCO, CA and YAVNE, ISRAEL--(Marketwired - Oct 23, 2014) - Medivation, Inc. ( NASDAQ : MDVN) and CureTech, Ltd.

Medivation: A Value In Biotech
Seeking Alpha - Aug 18, 2016
Medivation (NASDAQ:MDVN) is just such a company which is misunderstood by the market. It is a highly de-risked biotech with a commercialized, blockbuster drug (Xtandi in prostate cancer) already providing significant financial resources for the ...
How Much Medivation Can Really Fetch in a Buyout - 24/7 Wall St.

Exclusive: Medivation succumbs to pressure to explore sale - sources
Reuters - May 9, 2016
In 13 years, he built Medivation from a penny stock peddling a 20-year-old Russian treatment for hay fever into a $10 billion market capitalization oncology company.
Medivation Reportedly Yielding To Buyer Interest; Stock Surges - Investor's Business Daily

Enter a stock symbol to view the stock details.